High coverage and timeliness of vaccination of children under 6 years of age in Risaralda, Colombia

Hum Vaccin Immunother. 2023 Aug;19(2):2257424. doi: 10.1080/21645515.2023.2257424. Epub 2023 Sep 18.

Abstract

This study determined the coverage and timeliness of immunization in children <6 y from Risaralda, Colombia. A retrospective cross-sectional study evaluated data from a vaccination coverage and timeliness verification survey conducted in 2019, including 2457 children <6 y from Risaralda, Colombia. Variables included demographics, a record of vaccinations included in the Colombian Vaccination Plan, and date of immunization. Vaccination was defined as timely until 29 d after the day established by the plan. Coverage was over 95% for all vaccinations, except the boosters of diphtheria/pertussis/tetanus (DTP) and oral polio at 18 months (91.0%), influenza (85.6%), and yellow fever (49.2%). Most surveyed children demonstrated very high timeliness of vaccination, with values close to, or over, 90%, although there were exceptions for pentavalent (DTP+Haemophilus influenzae type B+hepatitis B) and polio vaccines at 6 months (79.4%), influenza (85.6%), and yellow fever (49.2%). Before the COVID-19 pandemic, Colombian Vaccination Plan demonstrated high coverage and timeliness of vaccination of children <6 y of age; however, timeliness for the third dose of DTP-Hib-HBV and polio showed opportunities for improvement.

Keywords: Colombia; DTP; immunization; immunization program; vaccination coverage; vaccine-preventable diseases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19*
  • Child
  • Child, Preschool
  • Colombia / epidemiology
  • Cross-Sectional Studies
  • Diphtheria-Tetanus-Pertussis Vaccine
  • Haemophilus influenzae type b*
  • Humans
  • Immunization, Secondary
  • Influenza Vaccines*
  • Influenza, Human*
  • Pandemics
  • Poliomyelitis*
  • Retrospective Studies
  • Vaccination
  • Yellow Fever* / epidemiology
  • Yellow Fever* / prevention & control

Substances

  • Diphtheria-Tetanus-Pertussis Vaccine
  • Influenza Vaccines

Grants and funding

This collaborative work with Universidad Tecnológicade Pereira was funded by Sanofi [under Grant:ID PER00095]. Sanofi did not participate in the management or data analysis of the study data.